Suven Life Sciences Q2 FY27 Share Price & Earnings Call Analysis
Part of: Nifty Microcap 250 · Nifty Total Market
- Market cap
- ₹7,591 Cr
- ROE
- -81.52%
- Price to sales
- 834.17
- Debt to equity
- 0.04
- 52W high / low
- ₹392 / ₹127
- Sales growth (5Y)
- -12.01%
- EBITDA margin
- -4366.92%
- Net profit margin
- -4020.82%
- Promoter holding
- 65.47%
- Sales (last year)
- ₹9 Cr
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.[1] [2]
Guidance scorecard · Q2 FY27 call
What Suven Life Sciences's management guided
and where it ranks in Healthcare Services
RevenueQ3 FY20 call
10–20%- Suven Pharma expects 15-20% growth in revenue for FY21 and beyond, based on expanded activities and capacities.
- Growth outlook is driven by a mix of contract manufacturing, specialty chemicals, new ANDA filings, and commercial CRAMS.
- The company acknowledges variability in quarter-to-quarter performance but maintains confidence in overall annual growth.
- FROM FY21 onwards, growth is expected to improve further with new infrastructure and expanded activities.
- The capacity utilization is effectively 100%, with a mix-and-match product approach allowing flexibility.
2 more points from Suven Life Sciences's call on revenue
Create a free account to keep reading this call
MarginsQ3 FY20 call
FlatSee what Suven Life Sciences said on margins — free account, 30 seconds.
CapexQ3 FY20 call
Planned- Suven Pharma has a total planned CAPEX of Rs. 320 crore, with Rs. 160 crore already spent and the balance expected to be spent by the end of FY20.
- For FY21, only replacement CAPEX of Rs. 50 crore is planned; no major new CAPEX is planned currently.
- The Rs. 320 crore CAPEX spans specialty chemicals, intermediates, formulation, and niche API (backward integration for internal and CRAMS customers) but not large-scale API commercial production.
- Capacity expansion is focused on reactor capacity (about 300 kiloliters), supporting a mix-and-match batch production model rather than fixed product capacity.
2 more points from Suven Life Sciences's call on capex
Create a free account to keep reading this call
FundraisingQ3 FY20 call
PlannedSee what Suven Life Sciences said on fundraising — free account, 30 seconds.
Order bookQ3 FY20 call
- Suven Pharma's commercial supply fluctuates with product demand, making it difficult to gauge a fixed order book or capacity utilization on a monthly basis.
- Capacity utilization is effectively 100% in terms of mix and match product manufacturing, but not continuously occupied by a single product.
- Management expects 15-20% growth next year based on the current number of projects and past performance, indicating a healthy order pipeline.
2 more points from Suven Life Sciences's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Suven Life Sciences latest results (Sep 2026)
Revenue
₹1 Cr
+30% YoY
Net profit
₹-107 Cr
Operating margin
-9242%
EPS
₹-3.78
Suven Life Sciences shareholding (Sep 2026)
Promoters
65.47%
−4.61 pp QoQ
FIIs
0.45%
−0.11 pp QoQ
DIIs
2.17%
−0.76 pp QoQ
Public
31.89%
+5.47 pp QoQ
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹870 Cr | — | |
| 2 | 40%+ | Flat | ₹576 Cr | 21.9 | |
| 3 | Indegene | 20–40% | Up 2%+ | ₹16,058 Cr | 37.7 |
| 4 | 20–40% | Up 2%+ | ₹1,716 Cr | 17.0 | |
| 5 | 20–40% | Up 2%+ | ₹622 Cr | 20.9 | |
| 6 | 20–40% | Flat | ₹1.23L Cr | 54.1 |
Sign up free to see every company in the sector ranking and track Suven Life Sciences.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingFinancials of Suven Life Sciences
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Suven Life Sciences
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 69.56% | 69.56% | 70.26% | 70.26% | 70.26% | 70.26% | 70.26% | 67.36% | 67.36% | 70.15% | 70.08% | 65.47% |
| FIIs + | 0.54% | 0.46% | 0.45% | 0.33% | 0.34% | 0.25% | 0.58% | 1.17% | 1.07% | 0.91% | 0.56% | 0.45% |
| DIIs + | 0.01% | 1.05% | 1.05% | 1.05% | 1.05% | 0.01% | 0.03% | 3.39% | 3.39% | 4.62% | 2.93% | 2.17% |
| Public + | 29.88% | 28.91% | 28.21% | 28.34% | 28.35% | 29.47% | 29.12% | 28.07% | 28.18% | 24.32% | 26.42% | 31.89% |
| No. of Shareholders | 74,003 | 68,959 | 66,116 | 63,975 | 63,537 | 64,603 | 66,159 | 64,921 | 64,381 | 63,915 | 66,791 | 67,431 |
Financials of Suven Life Sciences
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 | 1 |
| YoY Sales growth | -30% | -18% | -8% | -73% | -16% | -34% | -38% | +85% | -64% | +75% | +3% | +91% | +30% |
| Expenses + | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 | 112 |
| Operating Profit | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 | -111 |
| OPM % | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | -3,711% | -9,242% |
| Other Income + | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | -107 |
| Tax % | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit + | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | -107 |
| EPS in Rs | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | -4.83 | -3.78 |
Financials of Suven Life Sciences
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 7 | 9 |
| Sales growth | -4% | +9% | +15% | -54% | -96% | +7% | -12% | +14% | -14% | -43% | +7% | +55% | |
| Expenses + | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 291 | 406 |
| Operating Profit | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 | -397 |
| OPM % | 31% | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,999% | -4,367% |
| Other Income + | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 14 | 24 |
| Interest | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 | 7 |
| Profit before tax | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -276 | -382 |
| Tax % | 28% | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | 0% | |
| Net Profit + | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -382 |
| EPS in Rs | 7.87 | 5.20 | 6.31 | 8.95 | -1.73 | -6.82 | -5.22 | -7.73 | -5.42 | -4.82 | -7.37 | -10.48 | -14.82 |
| Dividend Payout % | 7% | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Suven Life Sciences
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 | 28 |
| Reserves | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 565 | 425 |
| Borrowings + | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | 17 | 16 |
| Other Liabilities + | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 16 | 37 |
| Total Liabilities | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 | 506 |
| Fixed Assets + | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 | 115 |
| CWIP | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 | 4 |
| Investments | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 181 | 14 |
| Other Assets + | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 367 | 374 |
| Total Assets | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 | 506 |
Financials of Suven Life Sciences
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 143 | 68 | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -115 | -155 | -300 |
| Cash from Investing Activity + | -110 | -39 | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 | -462 |
| Cash from Financing Activity + | 179 | -68 | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 | 757 |
| Net Cash Flow | 212 | -39 | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | -1 | -5 |
| Free Cash Flow | 25 | 10 | 79 | 28 | -92 | -137 | -102 | -147 | -119 | -113 | -193 | -305 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 113% | 93% | 111% | 57% | 262% | 114% | 119% | 104% | 91% | 95% | 93% | 106% |
Financials of Suven Life Sciences
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Inventory Days | 165 | 183 | 222 | 329 | 0 | |||||||
| Days Payable | 89 | 78 | 91 | 134 | ||||||||
| Cash Conversion Cycle | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Working Capital Days | 49 | 55 | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 | 506 |
| ROCE % | 13% | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% | -80% |
Guidance history
How Suven Life Sciences's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q3 FY20 call → | 10–20% | Flat | Planned | Planned | — |
| Q2 FY20 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY19 call → | 10–20% | Flat | Planned | None planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
27 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,947 stocks |
|---|---|---|
| Last 12 months | +48.3% | 83% |
| Last 6 months | −0.3% | 45% |
| Last 3 months | −21.0% | 9% |
The price is 31.5% below its all-time high of ₹392.05 (31 Aug 2026). Stocks more than 20% below their peak have their score halved, so 53 became 27.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,947 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Suven Life Sciences: 0.4 × 83 + 0.4 × 45 + 0.2 × 9 = 53, halved to 27 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 17 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Suven Life Sciences: frequently asked questions
What is Suven Life Sciences share price today?
Suven Life Sciences last traded at ₹268.65, with a market capitalisation of ₹7,591 Cr.
What were Suven Life Sciences's latest quarterly results?
For the quarter ended Sep 2026, Suven Life Sciences reported revenue of ₹1 Cr (+30% year on year) and net profit of ₹-107 Cr, with an operating margin of -9242%.
Is Suven Life Sciences's profit growing?
Net profit was ₹-107 Cr in Sep 2026 against ₹-77 Cr in Sep 2025.
What is Suven Life Sciences's EPS?
Suven Life Sciences's earnings per share for the quarter ended Sep 2026 was ₹-3.78.
What is the promoter holding in Suven Life Sciences?
Promoters held 65.47% of Suven Life Sciences in Sep 2026 (−4.61 pp versus Jun 2026).
How much do FIIs and DIIs hold in Suven Life Sciences?
In Sep 2026, foreign institutional investors held 0.45% and domestic institutions (including mutual funds) held 2.17% of Suven Life Sciences.
What is Suven Life Sciences's ROE and ROCE?
Suven Life Sciences's return on equity is -81.5% and its return on capital employed is -79.5%.
Does Suven Life Sciences pay a dividend?
Suven Life Sciences's dividend yield is 0% at the current price; see the Suven Life Sciences dividends page for past payouts.
Which sector does Suven Life Sciences belong to?
Suven Life Sciences is in the Healthcare Services sector. Its peer comparison and sector ranking are on this page.
What did Suven Life Sciences's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Suven Life Sciences's management.
How does Arthneeti AI analyse Suven Life Sciences?
Arthneeti reads Suven Life Sciences's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Suven Life Sciences's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
